Physician profile
Charles Wg Eifrig
NPI 1306812979
$281,826.15
in general payments reported to CMS, 2019-2025
29 companies · $17K in 2025
The $17K reported for 2025 was more than what 94% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40K · 2020: $13K · 2021: $43K · 2022: $54K · 2023: $62K · 2024: $54K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $62K · Consulting Fee: $46K · Travel and Lodging: $15K · Food and Beverage: $9,174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $61,700.00 |
| Consulting Fee | $46,367.00 |
| Travel and Lodging | $15,241.01 |
| Food and Beverage | $9,174.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $169,746.40 | 2019-2025 | Vabysmo, Susvimo, Lucentis |
| Alcon Research LLC | $45,280.22 | 2019-2025 | Ngenuity |
| Alcon Vision LLC | $38,983.96 | 2019-2025 | Constellation, Unity, Ngenuity |
| Carl Zeiss Meditec, INC. | $10,419.76 | 2019-2021 | |
| Allergan, INC. | $6,911.93 | 2019-2021 | |
| Regeneron Pharmaceuticals, INC. | $2,529.00 | 2024 | Eylea Hd |
| Beaver-Visitec International, INC. | $2,100.00 | 2024 | |
| Ocular Therapeutix, INC. | $1,500.00 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $1,454.78 | 2019-2025 | Eylea Hd, Eylea |
| Apellis Pharmaceuticals, INC. | $757.08 | 2023-2025 | Syfovre |
| Astellas Pharma US INC | $406.20 | 2023-2025 | Izervay |
| Eyepoint US, INC. | $324.87 | 2021-2023 | |
| Abbvie INC. | $222.26 | 2023-2025 | |
| Alimera Sciences, INC. | $210.92 | 2021-2024 | Iluvien, Yutiq |
| Dutch Ophthalmic, USA | $193.09 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $162.86 | 2019-2024 | Vabysmo |
| Coherus Oncology, INC. | $125.98 | 2022-2024 | |
| New World Medical,INC. | $124.18 | 2019 | |
| Bausch & Lomb Americas INC. | $64.94 | 2022-2023 | Xipere |
| Novartis Pharmaceuticals Corporation | $58.32 | 2019-2020 | |
| Astellas Pharma Global Development | $53.71 | 2024-2025 | Izervay |
| Sandoz INC. | $45.15 | 2024 | Cimerli |
| Biogen, INC. | $34.61 | 2022-2023 | |
| Pacira Therapeutics, INC. | $30.39 | 2020 | |
| Heidelberg Engineering, INC. | $27.38 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $20.71 | 2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Harrow Eye, LLC | $18.05 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Eifrig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.